Large-cap Health Care company Exelixis has logged a 1.5% change today on a trading volume of 1,691,874. The average volume for the stock is 2,107,553.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. Based in Alameda, United States the company has 1,310 full time employees and a market cap of $10,412,210,176.
The company is now trading 14.55% away from its average analyst target price of $31.83 per share. The 22 analysts following the stock have set target prices ranging from $18.9 to $38.0, and on average give Exelixis a rating of buy.
Over the last 52 weeks, EXEL stock has risen 62.6%, which amounts to a 30.5% difference compared to the S&P 500. The stock's 52 week high is $36.97 whereas its 52 week low is $19.2 per share. With its net margins declining an average -16.7% over the last 6 years, Exelixis may not have a strong enough profitability trend to support its stock price.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 1,830,208 | 207,765 | 11 | 0.0 |
| 2022 | 1,611,062 | 182,282 | 11 | 0.0 |
| 2021 | 987,538 | 111,781 | 11 | -66.67 |
| 2020 | 967,775 | 321,012 | 33 | -59.26 |
| 2018 | 853,826 | 690,070 | 81 | 138.24 |
| 2017 | 452,477 | 154,227 | 34 |
